FINARO
11.3.2022 14:32:08 CET | Business Wire | Pressemeddelelse
Finaro (tidligere Credorax) , en global betalingsudbyder og Europæisk bank, der styrker international handel gennem teknologiske og enkle betalingsløsninger, har i dag offentliggjort, at de har indgået en aftale med Shift4 omkring salget af Finaro til en værdi af 575 millioner USD. Det kombinerede tilbud, fra begge virksomheder, skaber en positiv synergi af et globalt betalingsnetværk med en betydelig POS og eCommerce platform, på tværs af en bred vifte af vertikaler, der servicerer store og komplekse virksomheder med unikke løsninger. Sammen vil Finaro og Shift4 være bedre i stand til at forsyne virksomheder med globale betalingsløsninger gennem flere kanaler, og stå side om side med nogle af de største aktører i betalingsbranchen, heriblandt Adyen, Nuvei og WorldPay.
“Dette køb understreger vores offensive bestræbelser på, at levere en unified commerce oplevelse overalt i verden. Denne handel viser tydeligt vores evne til at støtte eksisterende transformerende og globale kunder, såsom SpaceX Starlink & St. Jude Children’s Research Hospital,” fortæller Shift4s CEO Jared Isaacman.
Finaro vil levere den globale infrastruktur og den nødvendige banebrydende teknologi, for at føre Shift4s internationale ambitioner ud i livet om at levere en unified commerce løsning. Ved at integrere Finaros kapaciteter, vil Shift4 være i stand til at udvide virksomhedens nuværende serviceydelser overalt i verden, inklusiv dens næste generation af SkyTab POS-løsning, Shift4Shop e-handelsplatform og VenueNext stadiontilbud. Shift4 har også mere end 425 softwareintegrationer og over 200.000 merchants, hvoraf mange har en multinational tilstedeværelse, og giver øjeblikkelige internationale muligheder, som der nu kan åbnes for som et resultat af denne nyerhvervelse.
“Denne erhvervelse understreger, at vi har opnået, hvad vi har sat os for at opnå – at opbygge pålidelige betalingsbehandlingskapaciteter, som i sandhed er uden grænser, både hvad angår tilgængelighed og størrelse. At kunne anvende denne teknologi til SpaceXs Starlink-program, og andre der er tilsvarende i størrelsen, samtidig med også at kunne tilbyde vores virksomheder og partnere overalt i verden et bredere udvalg af produkter og serviceydelser, er realiseringen af dette mål på den mest konkrete måde, og vi er begejstrede over at blive en del af Shift 4- teamet,” fortæller Igal Rotem, CEO for Finaro.
For yderligere information om denne nyerhvervelse, besøg venligst præsentationssektionen på Shift4s Investor Relations website her .
###
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220311005243/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
